IL17A and infection: Schedule of treatment with anti-IL-17A mAb was set-up from 10 days post infection to distinguish IL-17A contributions to the lung pathology during advanced P. aeruginosa chronic infection (Fig. 5A) from those determined at the early/acute phase of infection in IL-17a−/− mice.